Measurable Residual IDH2 before Allogeneic Transplant for Acute Myeloid Leukemia

被引：1

作者：

Gui, Gege ^{[1
,2
]}

Dillon, Laura W. ^{[1
]}

Ravindra, Niveditha ^{[1
]}

Hegde, Pranay S. ^{[1
]}

Andrew, Georgia ^{[1
]}

Mukherjee, Devdeep ^{[1
]}

Wong, Zoe ^{[1
]}

Auletta, Jeffery J. ^{[3
,4
]}

El Chaer, Firas ^{[5
]}

Chen, Evan C. ^{[6
]}

Chen, Bin ^{[7
]}

Corner, Adam ^{[8
]}

Devine, Steven M. ^{[9
]}

Iyer, Sunil G. ^{[10
]}

Jimenez, Antonio M. Jimenez ^{[11
]}

De Lima, Marcos ^{[12
]}

Litzow, Mark R. ^{[13
]}

Kebriaei, Partow ^{[14
]}

Saber, Wael ^{[4
,15
]}

Spellman, Stephen R. ^{[4
,16
]}

Zeger, Scott L. ^{[2
]}

Page, Kristin M. ^{[4
,15
]}

Hourigan, Christopher S. ^{[17
]}

机构：

[1] Natl Heart Lung & Blood Inst, Hematol Branch, Lab Myeloid Malignancies, Bethesda, MD USA

[2] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Biostat, Baltimore, MD USA

[3] Nationwide Childrens Hosp, Hematol Oncol Bone Marrow Transplant & Infect Dis, Columbus, OH USA

[4] Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA

[5] Univ Virginia, Div Hematol & Oncol, Dept Med, Comprehens Canc Ctr,Med Ctr, Charlottesville, VA USA

[6] Dana Farber Canc Inst, Boston, MA USA

[7] Massachusetts Gen Hosp, Boston, MA USA

[8] Biorad Labs, Pleasanton, CA USA

[9] Natl Marrow Donor Program Be Match, CIBMTR Ctr Int Blood & Marrow Transplant Res, Minneapolis, MN USA

[10] Columbia Univ, Div Hematol & Oncol, Herbert Irving Comprehens Canc Ctr, Irving Med Ctr, New York, NY USA

[11] Miller Sch Med, Sylvester Comprehens Canc Ctr, Miami, FL USA

[12] Ohio State Univ, Div Hematol, Wexner Med Ctr, Columbus, OH USA

[13] Mayo Clin, Div Hematol, Rochester, MN USA

[14] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX USA

[15] Med Coll Wisconsin, Milwaukee, WI USA

[16] Natl Marrow Donor Program, Minneapolis, MN USA

[17] NIH, Myeloid Malignancies Program, Bethesda, MD USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-186822

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：5

共 50 条

[31] Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Lynn Quek
Muriel D. David
Alison Kennedy
Marlen Metzner
Michael Amatangelo
Alan Shih
Bilyana Stoilova
Cyril Quivoron
Maël Heiblig
Christophe Willekens
Véronique Saada
Samar Alsafadi
M. S. Vijayabaskar
Andy Peniket
Oliver A. Bernard
Sam Agresta
Katharine Yen
Kyle MacBeth
Eytan Stein
George S. Vassiliou
Ross Levine
Stephane De Botton
Anjan Thakurta
Virginie Penard-Lacronique
Paresh Vyas
Nature Medicine, 2018, 24 : 1167 - 1177
[32] Critical Roles Of The IDH2 Mutation In Development and Maintenance Of Acute Myeloid Leukemia
Ogawara, Yoko
Katsumoto, Takuo
Aikawa, Yukiko
Shima, Yutaka
Kagiyama, Yuki
Matsunaga, Hironori
Seki, Takahiko
Kitabayashi, Issay
BLOOD, 2013, 122 (21)
[33] Correlation between IDH2 mutations and disease status in acute myeloid leukemia
Eklund, Elizabeth A.
Raychaudhuri, Pradip
Platanias, Leonidas C.
LEUKEMIA & LYMPHOMA, 2010, 51 (12) : 2157 - 2158
[34] Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Thol, Felicitas
Damm, Frederik
Wagner, Katharina
Goehring, Gudrun
Schlegelberger, Brigitte
Hoelzer, Dieter
Luebbert, Michael
Heit, Wolfgang
Kanz, Lothar
Schlimok, Guenter
Raghavachar, Aruna
Fiedler, Walter
Kirchner, Hartmut
Heil, Gerhard
Heuser, Michael
Krauter, Juergen
Ganser, Arnold
BLOOD, 2010, 116 (04) : 614 - 616
[35] Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib
Quek, Lynn
David, Muriel D.
Kennedy, Alison
Metzner, Marlen
Amatangelo, Michael
Shih, Alan
Stoilova, Bilyana
Quivoron, Cyril
Heiblig, Mael
Willekens, Christophe
Saada, Veronique
Alsafadi, Samar
Vijayabaskar, M. S.
Peniket, Andy
Bernard, Oliver A.
Agresta, Sam
Yen, Katharine
MacBeth, Kyle
Stein, Eytan
Vassiliou, George S.
Levine, Ross
De Botton, Stephane
Thakurte, Anjan
Penard-Lacronique, Virginie
Vyas, Paresh
NATURE MEDICINE, 2018, 24 (08) : 1167 - +
[36] Importance of monitoring clonal dynamics of IDH2 mutations in Acute Myeloid Leukemia
Song, Jinming
David, Sallman
Padron, Eric
Sharma, Rohit
Hussaini, Mohammad
LABORATORY INVESTIGATION, 2019, 99
[37] Rapid IDH1/IDH2 Mutation Assessment in Acute Myeloid Leukemia (AML) and Glioma
Huynh, T.
Zhang, L.
Li, Y.
Solis, J.
Stanley, A.
Jin, H.
JOURNAL OF MOLECULAR DIAGNOSTICS, 2024, 26 (11): : S163 - S164
[38] Toward a Measurable Residual Disease-Based Algorithm for Selection of Allogeneic Hematopoietic Stem Cell Transplant in Acute Myeloid Leukemia
Thuy Ho
Gor, Juhi
Bouligny, Ian
Murray, Graeme
Maher, Keri
BLOOD, 2023, 142
[39] Differential prognosis impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia
Boissel, Nicolas
Nibourel, Olivier
Renneville, Aline
Huchette, Pascal
Dombret, Herve
Preudhomme, Claude
BLOOD, 2011, 117 (13) : 3696 - 3697
[40] Wild-type IDH2 is a potential therapeutic target for acute myeloid leukemia
Zeng, Peiting
Huang, Peng
CANCER RESEARCH, 2020, 80 (16)

← 1 2 3 4 5 →